A generic alternative indicated for Asthma and Breathing. Daily administration serves to decrease airway inflammation and prevents chronic obstructive pulmonary disease flare-ups.
Indicated to mitigate frequent COPD flares by reducing lung inflammation to support stable breathing and alleviate persistent chronic bronchitis symptoms.
Mechanism of Action
Roflumilast blocks an enzyme called PDE4, which is involved in the inflammatory process in the lungs. By inhibiting this enzyme, it reduces the swelling and mucus production that cause airway obstruction in COPD.
Route of Administration
Oral
Onset Time
Weeks for full effect
Duration
24 hours
Contraindications
Moderate to severe liver impairment, Hypersensitivity to roflumilast
Severe Adverse Events
Suicidal thoughts, Severe depression, Extreme weight loss, Liver injury
Common Side Effects
Headache, Mild nausea
Uncommon Side Effects
Diarrhea, Weight loss, Decreased appetite, Back pain
Information for Roflumilast is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
